Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The L1 protein is the major capsid protein of human papillomaviruses (HPVs). It self-assembles into virus-like particles (VLPs) that form the basis for current prophylactic HPV vaccines. L1 mediates capsid assembly, genome encapsulation, and host cell attachment. It is a highly immunogenic protein that induces neutralizing antibodies, preventing HPV infection and subsequent development of cervical cancer and other malignancies.
L1-based VLPs induce neutralizing antibodies against HPV, preventing infection.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Human Papillomavirus Type L1 Capsid Protein (L1).